Literature DB >> 9829375

Intraoperative detection of lung cancer by octreotide labeled to Indium-111.

V Pastore1, E Di Lieto, L Mansi, P F Rambaldi, M Santini, R Mancusi.   

Abstract

The contribution of radio surgery (RGS) using octreotide labeled with Indium-111 (In111) has been studied for surgical treatment of lung cancer. Thirteen patients were administered 111 Mbq of In111 octreotide intravenously. Scintigraphic images were preoperatively taken at 4, 24, and 48 hours after the tracer injection. Pulmonary resection and intraoperative evaluation by RGS technique were then performed to set the section limits. Histological staining of all the resected specimens and resection margins were assessed and their results were used as a confirmation of the RGS intraoperative findings. RGS is a simple method that can help the surgeon in the intraoperative assessment of bronchial, parenchymal, and parietal resection margins. Further research is needed to verify whether this method also may be useful in the intraoperative definition of the extent of mediastinal lymph node dissection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829375     DOI: 10.1002/(sici)1098-2388(199812)15:4<220::aid-ssu6>3.0.co;2-t

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  3 in total

1.  From the magic bullet to an effective therapy: the peptide experience.

Authors:  Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

Review 2.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

3.  Use of radioguided surgery with [111In]-pentetreotide in the management of an ACTH-secreting bronchial carcinoid causing ectopic Cushing's syndrome.

Authors:  E Grossrubatscher; F Vignati; P Dalino; M Possa; P A Belloni; A Vanzulli; M Bramerio; A Marocchi; O Rossetti; F Zurleni; P Loli
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.